EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain

Paloma Encinas iD, Antonio Lalueza-Blanco, Ana Isabel García-Vaquero, Martha I Nelson, Adolfo García-Sastre, Gustavo Del Real iD

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Paloma Encinas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, National Institute of Agricultural and Food Research and Technology (INIA-CSIC), Madrid, Spain. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Influenza A virus, Orthomyxoviridae Infections. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Swine influenza A viruses (SIVs) pose a zoonotic risk, with variants detected in humans in Europe. This study evaluated the efficacy of the 2021/2022 seasonal influenza vaccine against SIVs. Forty‐six postvaccination human sera were tested via hemagglutination inhibition (HI) assay against Spanish SIV genotypes. Seroprotection rate (SPR, HI titer ≥ 40) was 76% (95% CI: 64–88) and 91% (95% CI: 83–99) for human vaccine strains H1 and H3, respectively. SPRs were 67% (95% CI: 53–81) for pandemic swine H1, 64% (95% CI: 50–78) for human seasonal‐like H1, 17%–46% for Eurasian avian‐like H1, 15% (95% CI: 5–25) for human seasonal‐like H3 from the 1970s, and 83%–93% for human seasonal‐like H3 from the 2000s SIVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanInfluenza A virusOrthomyxoviridae InfectionsHumansSpainSwineAnimalsHemagglutination Inhibition TestsCross ReactionsAntibodies, ViralSeasonsMiddle AgedAdultFemaleMaleInfluenza A Virus, H1N1 SubtypeSwine DiseasesYoung Adult

Stichwörter der Autor:innen

influenza A viruspandemic riskreverse zoonosisswinevaccine

Substanzen

Influenza VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Department of Biotechnology, National Institute of Agricultural and Food Research and Technology (INIA-CSIC), Madrid, Spain.
  • Facultad de Veterinaria, Universidad Complutense de Madrid, Madrid, Spain.
  • Department of Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Occupational Health Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • National Center for Biotechnology Information, National Library of Medicine National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Paloma Encinas, Gustavo Del Real

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Encinas, P., Lalueza-Blanco, A., García-Vaquero, A. I., Nelson, M. I., García-Sastre, A., & Del Real, G. (2025). Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70158

Vancouver

Encinas P, Lalueza-Blanco A, García-Vaquero AI, Nelson MI, García-Sastre A, Del Real G. Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70158

BibTeX
@article{Encinas2025,
  author = {Encinas, Paloma and Lalueza-Blanco, Antonio and García-Vaquero, Ana Isabel and Nelson, Martha I and García-Sastre, Adolfo and Del Real, Gustavo},
  title = {Seasonal Influenza Vaccine 2021/2022 Provides Limited Cross Reactivity Against Contemporary Swine Influenza A Virus Strains in Spain},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70158}
}
Kostenlos starten →